Inhibrx Biosciences, Inc. (INBX)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
89. 83
-0.67
-0.7403%
$
1.33B Market Cap
- P/E Ratio
- Div Yield
146,400 Volume
-4.39 Eps
$ 90.5
Previous Close 
Want to track INBX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
Seekingalpha | 2 years ago
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Benzinga | 2 years ago
2026 © Marketlog. All Rights Reserved.
